These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 34425873)

  • 21. An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2022 Feb; 16(2):102396. PubMed ID: 35051686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review.
    Masyeni S; Iqhrammullah M; Frediansyah A; Nainu F; Tallei T; Emran TB; Ophinni Y; Dhama K; Harapan H
    J Med Virol; 2022 Jul; 94(7):3006-3016. PubMed ID: 35315098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2.
    Painter WP; Holman W; Bush JA; Almazedi F; Malik H; Eraut NCJE; Morin MJ; Szewczyk LJ; Painter GR
    Antimicrob Agents Chemother; 2021 May; 65(5):. PubMed ID: 33649113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo.
    Li Y; Liu M; Yan Y; Wang Z; Dai Q; Yang X; Guo X; Li W; Chen X; Cao R; Zhong W
    Viruses; 2022 May; 14(6):. PubMed ID: 35746614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
    Sheahan TP; Sims AC; Zhou S; Graham RL; Pruijssers AJ; Agostini ML; Leist SR; Schäfer A; Dinnon KH; Stevens LJ; Chappell JD; Lu X; Hughes TM; George AS; Hill CS; Montgomery SA; Brown AJ; Bluemling GR; Natchus MG; Saindane M; Kolykhalov AA; Painter G; Harcourt J; Tamin A; Thornburg NJ; Swanstrom R; Denison MR; Baric RS
    Sci Transl Med; 2020 Apr; 12(541):. PubMed ID: 32253226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets.
    Cox RM; Wolf JD; Plemper RK
    Nat Microbiol; 2021 Jan; 6(1):11-18. PubMed ID: 33273742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
    Andreou A; Trantza S; Filippou D; Sipsas N; Tsiodras S
    In Vivo; 2020 Jun; 34(3 Suppl):1567-1588. PubMed ID: 32503814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two?
    Eloy P; Le Grand R; Malvy D; Guedj J
    EBioMedicine; 2021 Dec; 74():103663. PubMed ID: 34768087
    [No Abstract]   [Full Text] [Related]  

  • 29. Antiviral Efficacy of Molnupiravir for COVID-19 Treatment.
    Bai Y; Shen M; Zhang L
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial.
    Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; O'Kane C; McAuley DF
    Trials; 2020 Jun; 21(1):462. PubMed ID: 32493473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results of two Phase 1, Randomized, Double-blind, Placebo-controlled, Studies (Ascending Single-dose and Multiple-dose Studies) to Determine the Safety, Tolerability, and Pharmacokinetics of Orally Administered LX9211 in Healthy Participants.
    Bundrant L; Hunt TL; Banks P; Gopinathan S; Boehm KA; Kassler-Taub K; Tyle P; Wilson A; Warner C; Wason S
    Clin Ther; 2021 Jun; 43(6):1029-1050. PubMed ID: 34108079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of molnupiravir for COVID-19 patients.
    Fatima M; Azeem S; Saeed J; Shahid A; Cheema HA;
    Eur J Intern Med; 2022 Aug; 102():118-121. PubMed ID: 35649740
    [No Abstract]   [Full Text] [Related]  

  • 34. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
    Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
    Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of molnupiravir in SARS-CoV-2-infected patients: A real-life experience.
    De Vito A; Colpani A; Bitti A; Zauli B; Meloni MC; Fois M; Denti L; Bacciu S; Marcia C; Maida I; Babudieri S; Madeddu G
    J Med Virol; 2022 Nov; 94(11):5582-5588. PubMed ID: 35855627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial.
    Nanni O; Viale P; Vertogen B; Lilli C; Zingaretti C; Donati C; Masini C; Monti M; Serra P; Vespignani R; Grossi V; Biggeri A; Scarpi E; Galardi F; Bertoni L; Colamartini A; Falcini F; Altini M; Massa I; Gaggeri R; Martinelli G
    Trials; 2020 Jul; 21(1):689. PubMed ID: 32736597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic.
    Khiali S; Khani E; B Rouy S; Entezari-Maleki T
    Future Microbiol; 2022 Mar; 17(5):377-391. PubMed ID: 35199608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro.
    Jonsdottir HR; Siegrist D; Julien T; Padey B; Bouveret M; Terrier O; Pizzorno A; Huang S; Samby K; Wells TNC; Boda B; Rosa-Calatrava M; Engler OB; Constant S
    Biomed Pharmacother; 2022 Jun; 150():113058. PubMed ID: 35658229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model.
    Johnson DM; Brasel T; Massey S; Garron T; Grimes M; Smith J; Torres M; Wallace S; Villasante-Tezanos A; Beasley DW; Comer JE
    Antiviral Res; 2023 Jan; 209():105492. PubMed ID: 36535309
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects.
    Qian HJ; Wang Y; Zhang MQ; Xie YC; Wu QQ; Liang LY; Cao Y; Duan HQ; Tian GH; Ma J; Zhang ZB; Li N; Jia JY; Zhang J; Aisa HA; Shen JS; Yu C; Jiang HL; Zhang WH; Wang Z; Liu GY
    Acta Pharmacol Sin; 2022 Dec; 43(12):3130-3138. PubMed ID: 35296780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.